Truist Financial Upgrades Collegium Pharmaceutical (NASDAQ:COLL) to “Strong-Buy”

Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by equities research analysts at Truist Financial to a “strong-buy” rating in a research report issued to clients and investors on Wednesday, Zacks reports.

A number of other equities analysts have also weighed in on COLL. Leerink Partners began coverage on shares of Collegium Pharmaceutical in a research report on Wednesday. They set an “outperform” rating and a $45.00 price target on the stock. Needham & Company LLC reduced their price objective on shares of Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Zacks Research lowered Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Weiss Ratings downgraded shares of Collegium Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, September 4th. Finally, Barclays reduced their price target on Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 19th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $48.50.

Collegium Pharmaceutical Trading Down 0.0%

Shares of COLL stock opened at $23.36 on Wednesday. The company has a debt-to-equity ratio of 3.32, a current ratio of 1.03 and a quick ratio of 0.84. The company has a market cap of $760.60 million, a price-to-earnings ratio of 18.84 and a beta of 0.72. Collegium Pharmaceutical has a 1-year low of $23.11 and a 1-year high of $50.79. The stock has a 50 day simple moving average of $31.10 and a 200-day simple moving average of $33.75.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.20. The business had revenue of $199.88 million for the quarter, compared to analyst estimates of $199.62 million. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. The company’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same quarter last year, the business earned $1.68 earnings per share. On average, equities research analysts expect that Collegium Pharmaceutical will post 6.51 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Vident Advisory LLC grew its stake in shares of Collegium Pharmaceutical by 1.9% in the 3rd quarter. Vident Advisory LLC now owns 15,466 shares of the specialty pharmaceutical company’s stock valued at $541,000 after purchasing an additional 281 shares during the last quarter. Quadrant Capital Group LLC increased its stake in shares of Collegium Pharmaceutical by 4.2% during the 4th quarter. Quadrant Capital Group LLC now owns 6,996 shares of the specialty pharmaceutical company’s stock worth $324,000 after purchasing an additional 282 shares in the last quarter. Atom Investors LP raised its stake in Collegium Pharmaceutical by 5.0% in the 4th quarter. Atom Investors LP now owns 6,124 shares of the specialty pharmaceutical company’s stock valued at $284,000 after purchasing an additional 294 shares during the last quarter. Assetmark Inc. lifted its stake in shares of Collegium Pharmaceutical by 9.3% during the 1st quarter. Assetmark Inc. now owns 3,923 shares of the specialty pharmaceutical company’s stock worth $130,000 after purchasing an additional 335 shares during the period. Finally, ProShare Advisors LLC raised its stake in Collegium Pharmaceutical by 5.0% during the fourth quarter. ProShare Advisors LLC now owns 7,507 shares of the specialty pharmaceutical company’s stock worth $348,000 after purchasing an additional 356 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.